TriangleHEALTH PROFESSIONAL · SOURCE READING
Spinal ependymoma with MYCN amplification (SP-EPN-MYCN)
Source: Childhood Cancer Genomics (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 30, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
Context: Central Nervous System Tumors / Ependymomas / Molecular Subgroups of Ependymoma
Median age at presentation was 31 years (range, 12–56 years).
High level of MYCN amplification was present at diagnosis and relapse.
SP-EPN-MYCN has a unique methylation profile compared with other spinal cord ependymomas, MYCN-amplified pediatric-type glioblastoma, and neuroblastoma.
For information about the treatment of childhood ependymoma, see Childhood Ependymoma Treatment.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Independent clinical review pending · Not medical advice